Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis

Overview of attention for article published in Clinical Rheumatology, December 2008

Altmetric Badge

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 31 Dimensions

Readers on

mendeley: 39 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Sarilumab for moderate to severe rheumatoid arthritis: Committee papers

Cited by National Institute for Health and Care Excellence on 14 Sep 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Tofacitinib for moderate to severe rheumatoid arthritis: Committee papers

Cited by National Institute for Health and Care Excellence on 30 Aug 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.